Accessibility Menu
Biote logo

Biote

(NASDAQ) BTMD

Current Price$2.30
Market Cap$69.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-77%
5 Year-77%
1 Year-44%
1 Month-4%

Biote Financials at a Glance

Market Cap

$69.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$188.16M

Net Income (TTM)

$15.60M

EPS (TTM)

$0.45

P/E Ratio

5.07

Dividend

$0.00

Beta (Volatility)

0.54 (Low)

Price

$2.30

Volume

4,229

Open

$2.31

Previous Close

$2.30

Daily Range

$2.24 - $2.32

52-Week Range

$1.27 - $4.75

Estimated Earnings Date

Aug 5, 2026

BTMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Biote

Industry

Pharmaceuticals

Employees

223

CEO

Bret Christensen, MBA

Headquarters

Irving, TX 75038, US

BTMD Financials

Key Financial Metrics (TTM)

Gross Margin

70.12%

Operating Margin

15.43%

Net Income Margin

8.29%

Return on Equity

-22.91%

Return on Capital

69.19%

Return on Assets

17.53%

Earnings Yield

19.72%

Dividend Yield

0.00%

Payout Ratio

9.22%

Stock Overview

Market Cap

$69.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.33M

Volume

4.23K

Avg. Volume

294.33K

Financials (TTM)

Gross Profit

$131.93M

Operating Income

$29.03M

EBITDA

$37.29M

Operating Cash Flow

$32.63M

Capital Expenditure

-$4.74M

Free Cash Flow

$27.89M

Cash & ST Invst.

$5.32M

Total Debt

$108.42M

Biote Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$44.94M

-8.3%

Gross Profit

$30.95M

-14.9%

Gross Margin

68.88%

N/A

Market Cap

$69.16MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$318.69K

N/A

Employees

217

N/A

Net Income

$2.28M

-83.4%

EBITDA

$6.29M

-70.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$5.32M

-87.2%

Total Debt

$108.42M

-0.9%

Accounts Receivable

$7.40M

-4.7%

Inventory

$19.88M

+47.8%

Long Term Debt

$101.56M

-1.0%

Short Term Debt

$6.86M

+1.0%

Return on Assets

17.53%

N/A

Return on Invested Capital

47.74%

N/A

Free Cash Flow

$2.73M

-43.5%

Operating Cash Flow

$3.90M

-39.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INOInovio Pharmaceuticals, Inc.
$1.21+4.31%
MCRBSeres Therapeutics, Inc.
$8.14+5.58%
SCLXScilex Holding Company
$9.93+23.05%
ACTUActuate Therapeutics Inc
$1.52+8.57%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$17.20-0.03%
RIVNRivian Automotive
$16.49-0.18%
CLROClearOne
$13.84+0.98%
CRNXCrinetics Pharmaceuticals
$83.53+0.99%

Questions About BTMD

What is the current price of Biote?

Biote is trading at $2.30 per share.

What is the 52-week range for Biote?

Over the past 52 weeks, Biote has traded between $1.27 and $4.75.

How much debt does Biote have?

As of the most recent reporting period, Biote reported total debt of $108.42M.

How much cash does Biote have on hand?

Biote reported $5.32M in cash and cash equivalents in its most recent financial results.

What is Biote’s dividend yield?

Biote does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.